Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 437-444

  Bain, G ^a   King, C D ^a   Rewolinski, M ^a,d   Schaab, K ^a   Santini, A M ^a   Shapiro, D ^a,d   Moran, M ^a,e   Van De Wetering De Rooij, S ^b   Roffel, A F ^b   Schuilenga Hut, P ^b   Milne, G L ^c   Lorrain, D S ^a   Li, Y ^a,f   Arruda, J M ^a   Hutchinson, J H ^a   Prasit, P ^a   Evans, J F ^a  

^a Amira Pharmaceuticals   (United States)

^b PRA Health Sciences   (Netherlands)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INTERCEPT PHARMACEUTICALS   (United States)

^e Versant Ventures   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLSULFANYL 1 [4 (6 METHOXY PYRIDIN 3 YL)BENZYL] 5 (PYRIDIN 2 YLMETHOXY) 1H INDOL 2 YL] 2,2 DIMETHYL PROPIONIC ACID; AM 103; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; LIPOXYGENASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TANDEM MASS SPECTROMETRY; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; LEUKOTRIENE B4; LEUKOTRIENE E4; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROPIONIC ACIDS; YOUNG ADULT;

EID: 77949875056     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.301     Document Type: Article

References (35)

1. Murphy, R.C. & Gijón, M.A. Biosynthesis and metabolism of leukotrienes. Biochem. J. 405, 379-395 (2007).
2. Mandal, A.K. et al. The membrane organization of leukotriene synthesis. Proc. Natl. Acad. Sci. U.S.A. 101, 6587-6592 (2004).
3. Byrum, R.S., Goulet, J.L., Grifths, R.J. & Koller, B.H. Role of the 5-lipoxygenase-activating protein (FLAP) in murine acute infammatory responses. J. Exp. Med. 185, 1065-1075 (1997).
4. Goulet, J.L., Snouwaert, J.N., Latour, A.M., Cofman, T.M. & Koller, B.H. Altered infammatory responses in leukotriene-defcient mice. Proc. Natl. Acad. Sci. U.S.A. 91, 12852-12856 (1994).
5. Ferguson, A.D. et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317, 510-512 (2007).
6. Young, R.N. Inhibitors of 5-lipoxygenase: a therapeutic potential yet to be fully realized? Eur. J. Med. Chem. 34, 671-685 (1999).
7. Evans, J.F., Ferguson, A.D., Mosley, R.T. & Hutchinson, J.H. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for infammatory diseases. Trends Pharmacol. Sci. 29, 72-78 (2008).
8. Berger, W., De Chandt, M.T. & Cairns, C.B. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int. J. Clin. Pract. 61, 663-676 (2007).
9. Dworski, R., Fitzgerald, G.A., Oates, J.A. & Sheller, J.R. Efect of oral prednisone on airway infammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med. 149, 953-959 (1994).
10. Gyllfors, P., Kumlin, M., Dahlén, S.E., Gaber, F., Ehrs, P.O. & Dahlén, B. Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Thorax 60, 902-908 (2005).
11. Funk, C.D. Leukotriene modifers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. 4, 664-672 (2005).
12. Holloway, J.W., Barton, S.J., Holgate, S.T., Rose-Zerilli, M.J. & Sayers, I. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 63, 1046-1053 (2008).
13. Parachuri, S. et al. Leukotriene E4-induced pulmonary infammation is mediated by the P2Y12 receptor. J. Exp. Med. 206, 2543-2555 (2009).
14. Turner, C.R. et al. In vitro and in vivo efects of leukotriene B4 antagonism in a primate model of asthma. J. Clin. Invest. 97, 381-387 (1996).
15. benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-Hutchinson, J.H. et al. 5-lipoxygenase-activating protein inhibitors: development: of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-propionic acid (AM103). J. Med. Chem. 52, 5803-5815 (2009).
16. Lorrain, D.S. et al. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl] -5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic infammation. J. Pharmacol. Exp. Ther. 331, 1042-1050 (2009).
17. Depré, M. et al. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. Clin. Pharmacol. Ther. 56, 22-30 (1994).
18. Chapman, K.R. et al. The efcacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am. J. Respir. Crit. Care Med. 151, A215 (1994).
19. Storms, W. et al. Treating asthma by blocking the lipoxygenase pathway. Am J. Respir. Crit. Care Med. 149, A377 (1995).
20. Konstans, M.W. et al. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr. Pulmon. 28s, 125-126 (2005).
21. Kumlin, M., Stensvad, F., Larsson, L., Dahlén, B. & Dahlén, S.E. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin. Exp. Allergy 25, 467-479 (1995).
22. Taylor, G.W. et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1, 584-588 (1989).
23. Smith, C.M., Christie, P.E., Hawksworth, R.J., Thien, F. & Lee, T.H. Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am. Rev. Respir. Dis. 144, 1411-1413 (1991).
24. Tanaka, S., Tanaka, H. & Abe, S. High dose of inhaled futicasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. Chest 124, 1768-1773 (2003).
25. Seymor, M.L. et al. Leukotriene and prostanoid pathway enzymes in bronchial biopsies of seasonal allergic asthmatics. Am. J. Respir. Crit. Care Med. 164, 2051-2056 (2001).
26. Cowburn, A.S., Holgate, S.T. & Sampson, A.P. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J. Immunol. 163, 456-465 (1999).
27. Hui, K.P. et al. Efect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 46, 184-189 (1991).
28. Nasser, S.M. et al. Efect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 49, 743-748 (1994).
29. Dahlén, B., Kumlin, M., Ihre, E., Zetterström, O. & Dahlén, S.E. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 52, 342-347 (1997).
30. Friedman, B.S. et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. 147, 839-844 (1993).
31. Diamant, Z. et al. The efect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol. 95, 42-51 (1995).
32. Gabor, F. et al. Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: Efects of treatment with zileuton. J. Allergy Clin. Immunol. 119, 1267-1268 (2007).
33. Uozumi, N. & Shimizu, T. Roles for cytosolic phospholipase A2α as revealed by gene-targeted mice. Prostaglandins Other Lipid Mediat. 68-69, 59-69 (2002).
34. Adler, D.H. et al. Inherited human cPLA(2α) defciency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J. Clin. Invest. 118, 2121-2131 (2008).
35. Bäck, M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc. Drugs Ther. 23, 41-48 (2009).